UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For
the Month of September 2026
Commission
File Number: 001-37353
SCINAI
IMMUNOTHERAPEUTICS LTD.
(Translation
of registrant’s name into English)
Jerusalem
BioPark, 2nd Floor
Hadassah
Ein Kerem Campus
Jerusalem,
Israel
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Explanatory
Note
On
September 21, 2026, Scinai Immunotherapeutics Ltd. issued a press release titled “Scinai Regains Compliance with Nasdaq Minimum Bid
Price Requirement.”
A
copy of the press release is furnished herewith as Exhibit 99.1.
This
Report on Form 6-K (other than the third paragraph thereof) is hereby incorporated by reference into the registrant’s
Registration Statements on Form S-8 (File Nos. 333-291460, 333-271293
and 333-239344) and
Form F-3 (File Nos. 333-295698
and 333-276767), to be a
part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently
filed or furnished..
Exhibit
Index
| Exhibit No. |
|
Description |
| 99.1 |
|
Press release dated September 21, 2026. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
| |
Scinai Immunotherapeutics Ltd. |
| |
|
|
| Date: September 21, 2026 |
By: |
/s/ Amir Reichman |
| |
|
Amir Reichman |
| |
|
Chief Executive Officer |
Exhibit 99.1
Scinai
Regains Compliance with Nasdaq Minimum Bid Price Requirement
Nasdaq
confirms compliance with Listing Rule 5550(a)(2) after 19 consecutive business days with a closing bid price at or above $1.00; minimum
bid price matter is closed
JERUSALEM,
September 21, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) (“Scinai” or the “Company”),
a biopharmaceutical company combining innovative immunology therapeutic development with a revenue-generating contract development and
manufacturing organization (“CDMO”), today announced that it has received written notification from Nasdaq Listing Qualifications
confirming that the Company has regained compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2)
and that the matter is now closed.
On
March 12, 2026, Nasdaq Staff notified Scinai that the Company’s American Depositary Shares (“ADSs”) had failed to maintain
a minimum bid price of $1.00 over the prior 30 consecutive business days. In its September 18, 2026 compliance letter, Nasdaq stated
that for the 19 consecutive business days from August 21, 2026 through September 17, 2026, the closing bid price of Scinai’s ADSs was
at $1.00 per share or greater. Accordingly, Nasdaq determined that Scinai had regained compliance with Listing Rule 5550(a)(2).
“Receiving
Nasdaq’s confirmation closes an important compliance matter for Scinai,” said Amir Reichman, Chief Executive Officer of Scinai.
“We appreciate Nasdaq Staff’s review and constructive engagement throughout the process. With this matter resolved, our focus remains
on commercial execution at Scinai Biopharma Services and disciplined advancement of our NanoAb programs.”
About
Scinai Immunotherapeutics
Scinai
Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company focused on the development of innovative immunology therapies and
the operation of a contract development and manufacturing organization. The Company is developing its NanoAb platform through research
collaboration and license arrangements with the Max Planck Society and University Medical Center Göttingen.
Scinai
also owns Scinai Biopharma Services Ltd., a CDMO providing development and manufacturing services to biotechnology and pharmaceutical
companies through facilities in Jerusalem and Yavne, Israel.
For
more information, please visit www.scinai.com.
Company
Contacts
Business
Development | +972 8 930 2529 | bd@scinai.com
Investor
Relations, Allele Capital Partners | +1 (561) 388-8178| BDeBeer@allelecapital.com
Forward-Looking
Statements
This
press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and
other applicable securities laws. These include statements regarding the Company’s continued commercial execution, CDMO growth and customer
programs, NanoAb development and the Company’s ability to maintain compliance with Nasdaq listing requirements.
These
statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results
to differ materially. Such risks include the Company’s ability to secure sufficient financing or non-dilutive funding on satisfactory
terms or at all; increase CDMO revenues and execute customer programs; maintain research and license arrangements; generate supportive
preclinical or clinical data; obtain regulatory approvals; secure development partners; maintain compliance with Nasdaq listing requirements;
and respond to competition and market, regulatory, geopolitical and economic conditions. Additional information appears in the Company’s
filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F filed on April 1, 2026. Forward-looking
statements speak only as of the date of this press release. Except as required by law, the Company undertakes no obligation to update
or revise them.
